Literature DB >> 19132849

Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease.

Janet K Snell-Bergeon1, David M Maahs, Lorraine G Ogden, Gregory L Kinney, John E Hokanson, Eric Schiffer, Marian Rewers, Harald Mischak.   

Abstract

BACKGROUND: In this study we sought to validate urinary biomarkers for diabetes and two common complications, coronary artery disease (CAD) and diabetic nephropathy (DN).
METHODS: A CAD score calculated by summing the product of a classification coefficient and signal amplitude of 15 urinary polypeptides was previously developed. Five sequences of biomarkers in the panel were identified as fragments of collagen alpha-1(I) and alpha-1(III). Prospectively collected urine samples available for analysis from 19 out of 20 individuals with CAD (15 with type 1 diabetes [T1D] and four without diabetes) and age-, sex-, and diabetes-matched controls enrolled in the Coronary Artery Calcification in Type 1 Diabetes study were analyzed for the CAD score using capillary electrophoresis and electrospray ionization mass spectrometry. Two panels of biomarkers that were previously defined to distinguish diabetes status were analyzed to determine their relationship to T1D. Three biomarker panels developed to distinguish DN (DNS) and two biomarker panels developed to distinguish renal disease (RDS) were examined to determine their relationship with renal function.
RESULTS: The CAD score was associated with CAD (odds ratio with 95% confidence interval, 2.2 [1.3-5.2]; P = 0.0016) and remained significant when adjusted individually for age, albumin excretion rate (AER), blood pressure, waist circumference, intraabdominal fat, glycosylated hemoglobin, and lipids. DNS and RDS were significantly correlated with AER, cystatin C, and serum creatinine. The biomarker panels for diabetes were both significantly associated with T1D status (P < 0.05 for both).
CONCLUSIONS: We validated a urinary proteome pattern associated with CAD and urinary proteome patterns associated with T1D and DN.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19132849      PMCID: PMC2939844          DOI: 10.1089/dia.2008.0040

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  32 in total

1.  Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry.

Authors:  Stefan Schaub; John Wilkins; Tracey Weiler; Kevin Sangster; David Rush; Peter Nickerson
Journal:  Kidney Int       Date:  2004-01       Impact factor: 10.612

Review 2.  Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future.

Authors:  David M Good; Visith Thongboonkerd; Jan Novak; Jean-Loup Bascands; Joost P Schanstra; Joshua J Coon; Anna Dominiczak; Harald Mischak
Journal:  J Proteome Res       Date:  2007-10-31       Impact factor: 4.466

Review 3.  The minimum information about a proteomics experiment (MIAPE).

Authors:  Chris F Taylor; Norman W Paton; Kathryn S Lilley; Pierre-Alain Binz; Randall K Julian; Andrew R Jones; Weimin Zhu; Rolf Apweiler; Ruedi Aebersold; Eric W Deutsch; Michael J Dunn; Albert J R Heck; Alexander Leitner; Marcus Macht; Matthias Mann; Lennart Martens; Thomas A Neubert; Scott D Patterson; Peipei Ping; Sean L Seymour; Puneet Souda; Akira Tsugita; Joel Vandekerckhove; Thomas M Vondriska; Julian P Whitelegge; Marc R Wilkins; Ioannnis Xenarios; John R Yates; Henning Hermjakob
Journal:  Nat Biotechnol       Date:  2007-08       Impact factor: 54.908

4.  High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine.

Authors:  Harald Mischak; Bruce A Julian; Jan Novak
Journal:  Proteomics Clin Appl       Date:  2007-07-10       Impact factor: 3.494

5.  Subclinical coronary and aortic atherosclerosis detected by magnetic resonance imaging in type 1 diabetes with and without diabetic nephropathy.

Authors:  Won Yong Kim; Anne Sofie Astrup; Matthias Stuber; Lise Tarnow; Erling Falk; René M Botnar; Cheryl Simonsen; Lotte Pietraszek; Peter R Hansen; Warren J Manning; Niels T Andersen; Hans-Henrik Parving
Journal:  Circulation       Date:  2006-12-26       Impact factor: 29.690

6.  Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns.

Authors:  Kasper Rossing; Harald Mischak; Hans-Henrik Parving; Per K Christensen; Michael Walden; Meike Hillmann; Thorsten Kaiser
Journal:  Kidney Int       Date:  2005-07       Impact factor: 10.612

7.  Urinary proteomic biomarkers in coronary artery disease.

Authors:  Lukas U Zimmerli; Eric Schiffer; Petra Zürbig; David M Good; Markus Kellmann; Laetitia Mouls; Andrew R Pitt; Joshua J Coon; Roland E Schmieder; Karlheinz H Peter; Harald Mischak; Walter Kolch; Christian Delles; Anna F Dominiczak
Journal:  Mol Cell Proteomics       Date:  2007-10-19       Impact factor: 5.911

8.  Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis.

Authors:  Dan Theodorescu; Stefan Wittke; Mark M Ross; Michael Walden; Mark Conaway; Ingo Just; Harald Mischak; Henry F Frierson
Journal:  Lancet Oncol       Date:  2006-03       Impact factor: 41.316

9.  Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry.

Authors:  Nils v Neuhoff; Thorsten Kaiser; Stefan Wittke; Ronald Krebs; Andrew Pitt; Aurea Burchard; Astrid Sundmacher; Brigitte Schlegelberger; Walter Kolch; Harald Mischak
Journal:  Rapid Commun Mass Spectrom       Date:  2004       Impact factor: 2.419

10.  Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis.

Authors:  Stephane Decramer; Stefan Wittke; Harald Mischak; Petra Zürbig; Michael Walden; François Bouissou; Jean-Loup Bascands; Joost P Schanstra
Journal:  Nat Med       Date:  2006-03-19       Impact factor: 53.440

View more
  26 in total

Review 1.  Novel biomarkers in type 1 diabetes.

Authors:  Yulan Jin; Jin-Xiong She
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 2.  Proteomic biomarkers in kidney disease: issues in development and implementation.

Authors:  Harald Mischak; Christian Delles; Antonia Vlahou; Raymond Vanholder
Journal:  Nat Rev Nephrol       Date:  2015-02-03       Impact factor: 28.314

Review 3.  Early diabetic nephropathy in type 1 diabetes: new insights.

Authors:  Petter Bjornstad; David Cherney; David M Maahs
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-08       Impact factor: 3.243

Review 4.  When are type 1 diabetic patients at risk for cardiovascular disease?

Authors:  Trevor J Orchard; Tina Costacou
Journal:  Curr Diab Rep       Date:  2010-02       Impact factor: 4.810

5.  Comprehensive human urine standards for comparability and standardization in clinical proteome analysis.

Authors:  Harald Mischak; Walter Kolch; Michalis Aivaliotis; David Bouyssié; Magali Court; Hassan Dihazi; Gry H Dihazi; Julia Franke; Jérôme Garin; Anne Gonzalez de Peredo; Alexander Iphöfer; Lothar Jänsch; Chrystelle Lacroix; Manousos Makridakis; Christophe Masselon; Jochen Metzger; Bernard Monsarrat; Michal Mrug; Martin Norling; Jan Novak; Andreas Pich; Andrew Pitt; Erik Bongcam-Rudloff; Justyna Siwy; Hitoshi Suzuki; Visith Thongboonkerd; Li-Shun Wang; Jérôme Zoidakis; Petra Zürbig; Joost P Schanstra; Antonia Vlahou
Journal:  Proteomics Clin Appl       Date:  2010-02-03       Impact factor: 3.494

Review 6.  Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease.

Authors:  Cécile Caubet; Chrystelle Lacroix; Stéphane Decramer; Jens Drube; Jochen H H Ehrich; Harald Mischak; Jean-Loup Bascands; Joost P Schanstra
Journal:  Pediatr Nephrol       Date:  2009-07-15       Impact factor: 3.714

7.  Application of Proteomic Analysis to Renal Disease in the Clinic.

Authors:  Bruce A Julian; Hitoshi Suzuki; Goce Spasovski; Yusuke Suzuki; Yasuhiko Tomino; Jan Novak
Journal:  Proteomics Clin Appl       Date:  2009-01-01       Impact factor: 3.494

8.  Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.

Authors:  Sten Andersen; Harald Mischak; Petra Zürbig; Hans-Henrik Parving; Peter Rossing
Journal:  BMC Nephrol       Date:  2010-11-01       Impact factor: 2.388

9.  Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology.

Authors:  David M Maahs; Justyna Siwy; Angel Argilés; Marie Cerna; Christian Delles; Anna F Dominiczak; Nathalie Gayrard; Alexander Iphöfer; Lothar Jänsch; George Jerums; Karel Medek; Harald Mischak; Gerjan J Navis; Johannes M Roob; Kasper Rossing; Peter Rossing; Ivan Rychlík; Eric Schiffer; Roland E Schmieder; Thomas C Wascher; Brigitte M Winklhofer-Roob; Lukas U Zimmerli; Petra Zürbig; Janet K Snell-Bergeon
Journal:  PLoS One       Date:  2010-09-28       Impact factor: 3.240

Review 10.  Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm.

Authors:  Jochen Metzger; Peter B Luppa; David M Good; Harald Mischak
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.